Clinical Trial Update: Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder [Phase 2, Phase 3]

View source ↗

Summary

Pioglitazone is being studied as an adjunctive treatment for moderate to severe major depressive disorder in Phase 2 and Phase 3 trials. The study status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Major Depressive Disorder | Phase 2, Phase 3 | Status: COMPLETED